Gathering and analyzing patient experience data in a real-world setting is a key challenge for many

By HEOR Staff Writer

January 18, 2023

Gathering and analyzing patient experience data in a real-world setting is a key challenge for many. To explore this further, ISPOR in Vienna held a second plenary panel featuring experts in the field. What did they discuss?

The panel discussed the importance of rigor in choosing, implementing, and analyzing patient experience data in non-randomized, uncontrolled study designs. Dr. Burgos spoke about the Darwin EU initiative and the importance of stakeholder engagement and capacity building to facilitate patient experience data collection. Professor Devlin discussed the implementation of patient-reported outcome data capture and the PROMs initiatives in the UK, Canada, and New Zealand. Dr. Perfetto spoke about the Core Impact initiative in the US, which standardizes patient experience data collection and the use of core outcome sets.

The panel highlighted the need for further guidance and collaboration with stakeholders to ensure patient experience data is used to inform regulatory decision-making.

Reference url

Recent Posts

Global Growth and Challenges in Pharmacy Vaccination Training

By João L. Carapinha

May 13, 2026

Pharmacy Vaccination Training has expanded rapidly worldwide, with the number of countries offering pharmacist vaccination programs rising from 12 in 2016 to 64 by 2024. This 433 percent growth means training is now available in every nation where pharmacists may administer vaccines, including pr...
Key Strategies in Neonatal Infection Management: Insights from NICE Guideline NG195
The NICE guideline NG195 establishes a structured framework for neonatal infection management in newborns up to 28 days corrected gestational age, treating at-risk pregnant individuals, and managing suspected or confirmed infections in neonates. It emphasizes timely recognition to avoid delays, j...
Merck Oncology Advancements Highlight Long-Term Data and Pipeline Progress at ASCO 2026
Merck oncology advancements continue to deliver meaningful progress for patients. New long-term data from multiple trials highlight sustained survival benefits across lung cancer, breast cancer, melanoma, and other tumor types. These advancements will feature prominently at the 2026 American S...